Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00305942 · ClinicalTrials.gov registry record · Phase 2
Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer
A Phase 2 study of Carcinoma, Small Cell, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
- 16
- Study locations
NCT00305942 is a Phase 2 study of Carcinoma, Small Cell that has completed, run by SCRI Development Innovations. The registered enrollment target is 61 participants, below the 106-participant average among 3 other Carcinoma, Small Cell trials with a reported enrollment target (42% lower). The trial reports 16 study locations across 12 states.
The verdict
NCT00305942, a Phase 2 study of Carcinoma, Small Cell, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
- 16
- Study locations
Study Summary
This proposed phase II trial will investigate the combination of topotecan/carboplatin in the first-line treatment of patients with extensive-stage SCLC. Topotecan/platinum regimens are emerging as common treatments for patients with extensive-stage disease. This trial will be one of the first clinical trials to evaluate a combination of weekly topotecan and carboplatin in the first-line treatment of extensive-stage SCLC.
Conditions Studied
Interventions
- DRUG Topotecan
- DRUG carboplatin
Study Locations (16)
Tennessee
- Associates in Hematology Oncology - Chattanooga
- Family Cancer Center - Collierville
- Tennessee Oncology, PLLC - Nashville
Florida
- Florida Cancer Specialists - Fort Myers
- Watson Clinic Center for Cancer Care and Research - Lakeland
Kentucky
- Graves-Gilbert Clinic - Bowling Green
- Consultants in Blood Disorders and Cancer - Louisville
Alabama
- Northeast Alabama Regional Medical Center - Anniston
Arkansas
- Northeast Arkansas Clinic - Jonesboro
Georgia
- Northeast Georgia Medical Center - Gainesville
Louisiana
- Hematology Oncology Life Center - Alexandria
Maine
- Mercy Hospital - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2006-03 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00305942
The ClinicalTrials.gov registry entry for NCT00305942 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 106-participant average among 3 other Carcinoma, Small Cell trials with a reported enrollment target (42% lower). The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Small Cell appearing as the primary indexed condition, and to 2 interventions - of which Topotecan is the first listed.
NCT00305942 reports 16 study locations spanning 12 distinct geographic areas - top geographies include Tennessee, Florida, Kentucky.
Frequently Asked Questions
What is clinical trial NCT00305942 about?
NCT00305942 is a clinical study titled "Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer". This proposed phase II trial will investigate the combination of topotecan/carboplatin in the first-line treatment of patients with extensive-stage SCLC. Topotecan/platinum regimens are emerging as common treatments for patients with extensive-stage disease. This trial will be one of the first clini...
What is the current status of trial NCT00305942?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2006-03. Estimated completion is 2009-11.
What conditions does trial NCT00305942 study?
This clinical trial studies the following conditions: Carcinoma, Small Cell.
What interventions are being tested in trial NCT00305942?
The interventions under investigation include: Topotecan (DRUG), carboplatin (DRUG).
Who is sponsoring clinical trial NCT00305942?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00305942 being conducted?
This trial has 16 study locations across Alabama, Arkansas, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Small Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned
COMPLETED · Phase 2
-
Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer
COMPLETED · Phase 2
-
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.